Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: NON-breast HER2+ Malignancies
Interventions: DRUG: NJH395
Sponsor: Novartis Pharmaceuticals